Divi’s Laboratories Limited (NSE: DIVISLAB) is a pharmaceutical company specializing in the manufacture of active pharmaceutical ingredients (APIs) and intermediates. The company operates globally, with facilities in India, the United States, and Europe, and serves customers in over 60 countries. Divi’s Laboratories is known for its strong focus on quality and innovation, and has a reputation for delivering high-quality products and services to its customers. The company’s API portfolio includes a wide range of products, including anti-cancer, anti-inflammatory, anti-viral, and cardiovascular drugs.
Divi’s Laboratories, a pharmaceutical company, announced its Q3FY23 results. The company reported a consolidated total income of Rs 1,822 crores for Q3FY23, a decrease from the total income of Rs 2,510 crores during the same quarter of last year. The Profit before Tax (PBT) for Q3FY23 was Rs 436 crores, a decrease from the PBT of Rs 1,034 crores in the corresponding quarter of the previous year. The Profit after Tax (PAT) for Q3FY23 was Rs 307 crores, also a decrease from the PAT of Rs 902 crores in the same quarter of the previous year. The company’s 9-month (9MFY23) performance showed a PAT of Rs 1,502 crores on a total income of Rs 6,099 crores, a decrease from the PAT of Rs 2,066 crores on a total income of Rs 6,503 crores in the previous period.